Alpha 2.0
Login Register
» Authors » Maxensia Owor

Maxensia Owor

Explore the profile of Maxensia Owor including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 25
Citations 539
Followers 0
Related Specialties
Infectious Diseases
General Medicine
Pediatrics
Top 10 Co-Authors
Mary Glenn Fowler
Dhayendre Moodley
Lameck Chinula
Taha E Taha
Lynda Stranix-Chibanda
Patricia M Flynn
Avy Violari
Sufia Dadabhai
Renee Browning
Nahida Chakhtoura
Published In
J Acquir Immune Defic Syndr
AIDS
Clin Infect Dis
Lancet
mSphere
Affiliations
Soon will be listed here.
Recent Articles
11.
Progesterone and prolactin levels in pregnant women living with HIV who delivered preterm and low birthweight infants: A nested case-control study
Chi B, Sebikari D, Brummel S, DeMarrais P, Chamanga R, Owor M, et al.
PLoS One . 2023 Jan; 18(1):e0280730. PMID: 36689442
Background: Antiretroviral therapy (ART) is associated with high rates of adverse birth outcomes, including preterm birth and low birthweight. Studies suggest that progesterone and prolactin may play important intermediary roles....
12.
Twenty years of Prevention of Mother to Child HIV Transmission: research to implementation at a national referral hospital in Uganda
Namara-Lugolobi E, Namukwaya Z, Owor M, Ouma J, Namale-Matovu J, Nakabiito C, et al.
Afr Health Sci . 2022 Nov; 22(Spec Issue):22-33. PMID: 36321115
Background: Over 90% of new paediatric HIV infections are acquired through mother to child transmission. Prevention of mother to child HIV transmission (PMTCT) research in sub-Saharan Africa informed WHO guidelines...
13.
Self-reported Antiretroviral Adherence: Association With Maternal Viral Load Suppression in Postpartum Women Living With HIV-1 From Promoting Maternal and Infant Survival Everywhere, a Randomized Controlled Trial in Sub-Saharan Africa and India
Nevrekar N, Butler K, Shapiro D, Atuhaire P, Taha T, Makanani B, et al.
J Acquir Immune Defic Syndr . 2022 Sep; 92(1):76-83. PMID: 36170749
Introduction: Optimal adherence to antiretroviral therapy (ART) is crucial to promoting maternal-infant health. Setting: Fourteen sites in 7 countries within sub-Saharan Africa and India. Methods: The multicomponent, open-label strategy PROMISE...
14.
Neurodevelopmental outcomes of HIV/antiretroviral drug perinatally exposed uninfected children aged 3-6 years
Fowler M, Hanrahan C, Yende N, Stranix-Chibanda L, Chipato T, Maliwichi L, et al.
AIDS . 2022 Jun; 36(11):1533-1543. PMID: 35730383
Objective: Given the roll out of maternal antiretroviral therapy (ART) for prevention-of-perinatal-HIV-transmission, increasing numbers of children are perinatally HIV/antiretroviral exposed but uninfected (CAHEU). Some studies suggest CAHEU may be at...
15.
Maternal Human Immunodeficiency Virus (HIV) Drug Resistance Is Associated With Vertical Transmission and Is Prevalent in Infected Infants
Boyce C, Sils T, Ko D, Wong-On-Wing A, Beck I, Styrchak S, et al.
Clin Infect Dis . 2021 Sep; 74(11):2001-2009. PMID: 34467974
Background: We aimed to assess if maternal human immunodeficiency virus (HIV) drug resistance is associated with an increased risk of HIV vertical transmission and to describe the dynamics of drug...
16.
Association of Maternal Viral Load and CD4 Count With Perinatal HIV-1 Transmission Risk During Breastfeeding in the PROMISE Postpartum Component
Flynn P, Taha T, Cababasay M, Butler K, Fowler M, Mofenson L, et al.
J Acquir Immune Defic Syndr . 2021 Jun; 88(2):206-213. PMID: 34108383
Background: Breastfeeding mothers with HIV infection not qualifying for antiretroviral therapy (ART) based on country-specific guidelines at the time of the Promoting Maternal-Infant Survival Everywhere trial and their uninfected neonates...
17.
Pharmacokinetics and Safety of Zidovudine, Lamivudine, and Lopinavir/Ritonavir in HIV-infected Children With Severe Acute Malnutrition in Sub-Saharan Africa: IMPAACT Protocol P1092
Owor M, Tierney C, Ziemba L, Browning R, Moye J, Graham B, et al.
Pediatr Infect Dis J . 2021 Jan; 40(5):446-452. PMID: 33464021
Background: Severe acute malnutrition (SAM) may alter the pharmacokinetics (PK), efficacy, and safety of antiretroviral therapy. The phase IV study, IMPAACT P1092, compared PK, safety, and tolerability of zidovudine (ZDV),...
18.
Pregnancy Outcomes of Women Conceiving on Antiretroviral Therapy (ART) Compared to Those Commenced on ART During Pregnancy
Theron G, Brummel S, Fairlie L, Pinilla M, McCarthy K, Owor M, et al.
Clin Infect Dis . 2020 Jun; 73(2):e312-e320. PMID: 32564058
Background: Globally, the number of infected women of childbearing age living with human immunodeficiency virus (HIV) and conceiving on antiretroviral therapy (ART) is increasing. Evidence of ART safety at conception...
19.
Maternal Humoral Immune Responses Do Not Predict Postnatal HIV-1 Transmission Risk in Antiretroviral-Treated Mothers from the IMPAACT PROMISE Study
Hompe E, Jacobson D, Eudailey J, Butler K, Edwards W, Pollara J, et al.
mSphere . 2019 Oct; 4(5). PMID: 31645430
To design immune interventions that can synergize with antiretroviral therapy (ART) to reduce the rate of HIV mother-to-child transmission (MTCT), it is essential to characterize maternal immune responses in the...
20.
Risk Factors for Adverse Birth Outcomes in the PROMISE 1077BF/1077FF Trial
Sebikari D, Farhad M, Fenton T, Owor M, Stringer J, Qin M, et al.
J Acquir Immune Defic Syndr . 2019 Jul; 81(5):521-532. PMID: 31295174
Background: In the multicountry PROMISE 1077BF/1077FF trial, the risk of low birth weight (LBW; <2500 g) and preterm delivery (PTD; <37 weeks) was significantly higher among women initiating a protease...